engleski

Adjuvant activity of levamisole for experimental F18ac+ Escherichia coli oral vaccine against porcine post-weaning colibacillosis

Escherichia coli strain expressing F18 fimbriae has been suggested to possess lower capability of stimulation of immune responses in weaned pigs than F4+ E. coli strain. In order to overcome this problem, we used levamisole as a candidate mucosal adjuvant for experimental F18ac+ E. coli oral vaccine. We hypothesized that levamisole may exert its adjuvant activity in weaned pigs vaccinated with experimental F18+ E. coli oral vaccine by triggering immune effector sites of the gut-associated lymphoid tissue (GALT), such as mesenteric lymph node (MLN). Therefore, flow cytometry was used to analyze CD25, SWC7, and SWC9 activation antigens expression on the surfaces of MLN and spleen T cells, B cells and macrophages, respectively, isolated from levamisole-primed F18ac+ non-enterotoxigenic E. coli (ETEC)-vaccinated (N = 5) or sham-vaccinated (N = 5) challenge-inoculated weaned pigs. Our results have shown that levamisole synergizes experimental F18ac+ E. coli oral vaccine in stimulating activation of CD25+ T cells, SWC7+ B cells, and SWC9+ macrophages preferentially in the MLN of challenged weaned pigs.

levamisole; cell-mediated immune response; weaned pigs; vaccination; colibacillosis

-